Federated Investors Inc. PA raised its stake in Zafgen Inc (NASDAQ:ZFGN) by 27.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 129,661 shares of the biopharmaceutical company’s stock after buying an additional 27,533 shares during the period. Federated Investors Inc. PA’s holdings in Zafgen were worth $412,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the company. Spark Investment Management LLC boosted its stake in Zafgen by 73.5% in the third quarter. Spark Investment Management LLC now owns 347,500 shares of the biopharmaceutical company’s stock valued at $1,150,000 after buying an additional 147,200 shares during the period. Dimensional Fund Advisors LP boosted its stake in Zafgen by 41.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 306,462 shares of the biopharmaceutical company’s stock valued at $975,000 after buying an additional 89,805 shares during the period. Finally, State Street Corp boosted its stake in Zafgen by 4.2% in the fourth quarter. State Street Corp now owns 352,963 shares of the biopharmaceutical company’s stock valued at $1,122,000 after buying an additional 14,353 shares during the period. Institutional investors and hedge funds own 50.64% of the company’s stock.
Zafgen Inc (NASDAQ:ZFGN) opened at 4.60 on Friday. Zafgen Inc has a one year low of $2.89 and a one year high of $8.28. The firm’s market cap is $125.81 million. The company has a 50-day moving average price of $4.19 and a 200-day moving average price of $3.65.
Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings results on Thursday, March 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.12. During the same period in the prior year, the firm posted ($0.85) earnings per share. Equities analysts predict that Zafgen Inc will post ($2.09) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was published by Web Breaking News and is the sole property of of Web Breaking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at http://www.webbreakingnews.com/2017/03/26/zafgen-inc-zfgn-position-boosted-by-federated-investors-inc-pa.html.
ZFGN has been the topic of several analyst reports. Zacks Investment Research upgraded Zafgen from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Thursday, January 12th. FBR & Co restated a “marketperform” rating on shares of Zafgen in a report on Tuesday, March 7th. Finally, Cowen and Company restated a “hold” rating on shares of Zafgen in a report on Friday, March 10th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Zafgen presently has an average rating of “Hold” and a consensus price target of $16.42.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Want to see what other hedge funds are holding ZFGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zafgen Inc (NASDAQ:ZFGN).
Receive News & Ratings for Zafgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.